Oppenheimer Analysts Give Regeneron Pharmaceuticals (REGN) a $440.00 Price Target
Oppenheimer set a $440.00 price objective on Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Sunday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
REGN has been the subject of a number of other research reports. JPMorgan Chase & Co. set a $405.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a hold rating in a research report on Wednesday, November 7th. Canaccord Genuity upped their price target on shares of Regeneron Pharmaceuticals from $390.00 to $410.00 and gave the stock a hold rating in a research report on Thursday, October 11th. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, October 1st. They set a neutral rating and a $415.00 price target for the company. BidaskClub lowered shares of Regeneron Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, August 11th. Finally, Cowen reaffirmed a hold rating and set a $385.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 6th. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $408.42.
NASDAQ:REGN opened at $372.80 on Friday. The company has a quick ratio of 3.30, a current ratio of 4.04 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $39.57 billion, a PE ratio of 27.80, a PEG ratio of 1.64 and a beta of 1.36. Regeneron Pharmaceuticals has a 1-year low of $281.89 and a 1-year high of $416.49.
In other news, Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction on Monday, September 24th. The shares were sold at an average price of $388.65, for a total value of $777,300.00. Following the completion of the sale, the director now owns 13,000 shares of the company’s stock, valued at $5,052,450. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 12.42% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. Vanguard Group Inc. now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after acquiring an additional 75,868 shares in the last quarter. Morgan Stanley increased its position in shares of Regeneron Pharmaceuticals by 70.6% in the third quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after acquiring an additional 192,236 shares in the last quarter. Legal & General Group Plc increased its position in shares of Regeneron Pharmaceuticals by 2.5% in the third quarter. Legal & General Group Plc now owns 360,002 shares of the biopharmaceutical company’s stock worth $145,455,000 after acquiring an additional 8,792 shares in the last quarter. Kepos Capital LP acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $1,928,000. Finally, Standard Life Aberdeen plc increased its position in shares of Regeneron Pharmaceuticals by 13.0% in the third quarter. Standard Life Aberdeen plc now owns 20,839 shares of the biopharmaceutical company’s stock worth $8,421,000 after acquiring an additional 2,403 shares in the last quarter. 67.24% of the stock is owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.